Seelos Therapeutics 'temporarily' stops study in rare neuro disorder for business reasons
Microcap biotech Seelos Therapeutics is halting enrollment of its study in spinocerebellar ataxia type 3 (also known as Machado-Joseph disease) because of “financial considerations,” and in order to focus on other studies, the company said today, adding that the pause would be temporary.
The study will continue with the patients who have already enrolled, and the data from them will be used to decide whether to continue enrolling others in the future.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters